Details for Patent: 8,092,832

Summary of US Patent 8,092,832

United States Patent 8,092,832, granted on January 10, 2012, to Eli Lilly and Company, covers novel pharmaceutical compounds and their use in treating specific medical conditions. The patent's core claim revolves around a class of kinase inhibitors targeting aberrant signaling pathways associated with cancer and other diseases. It encompasses compositions, methods of treatment, and intermediate compounds.

This analysis provides an in-depth review of the patent's scope and claims, maps the patent landscape, and offers insights into its strategic significance, focusing on its claims' breadth, patent positioning, and relevant legal considerations.

What is the Scope of Patent 8,092,832?

Broad Overview

The patent's scope largely centers on a specific class of quinazoline-based kinase inhibitors designed to modulate receptor tyrosine kinases (RTKs), particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Its claims extend to compounds, pharmaceutical compositions, and methods of treatment involving these inhibitors.

Key Structural Features

The patent claims compounds characterized by:

• A quinazoline core, substituted at various positions
• Specific substituents (e.g., aryl, heteroaryl groups, and other functional groups) that enhance kinase selectivity and potency
• Pharmacophore features designed for improved pharmacokinetics (absorption, distribution, metabolism, excretion—ADME)

Classes of Compounds Covered:

Claims’ Scope

The patent specifies claims across multiple levels of breadth:

1. Compound claims (Claims 1-20): Covering multiple chemical structures characterized by specific substitutions on the quinazoline core.
2. Method claims (Claims 21-35): Use of compounds for treating cancers such as non-small cell lung carcinoma (NSCLC), breast cancer, and other RTK-driven diseases.
3. Composition claims (Claims 36-50): Pharmaceutical formulations containing the compounds.
4. Intermediate claims: Synthesis methods and intermediate compounds useful for producing the active agents.

Representative Claims Example

• Claim 1 (Compound claim): A compound comprising a quinazoline core substituted with specific aryl and heteroaryl groups, exhibiting inhibitory activity against EGFR and HER2 kinases.
• Claim 21 (Method claim): A method of treating cancer comprising administering a therapeutically effective amount of the claimed compound.

Legal and Strategic Considerations

• The claims' breadth effectively covers a wide chemical space of kinase inhibitors, prioritizing selectivity and potency.
• The patent emphasizes method of treatment claims—crucial for pharmaceutical patent enforcement.
• Dependent claims specify particular substituents, providing fallback options for infringement analysis.

Patent Landscape Analysis of Related Art

Key Patent Families and Prior Art

This landscape reveals multiple players with overlapping compounds, emphasizing intense competition in kinase inhibitors, especially for oncology indications.

Major Litigation and Patent Challenges

• FTO (Freedom-to-Operate) risks exist due to overlapping claims with earlier art.
• Litigation history: No significant litigation associated with US 8,092,832, but potential challenges could arise over claim scope, especially if similar compounds are claimed.

Market and Regulatory Landscape

• The patent covers compounds aligned with approved drugs like Erlotinib and Gefitinib, indicating strategic positioning.
• US FDA approvals for drugs derived from related compounds occurred between 2004-2010, confirming market relevance during patent life.

Comparison with Key Related Patents

Implications for Patent Strategies

• The patent’s specific compound claims allow narrower design-around options.
• The method claims extend protection beyond compounds, vital for combination therapies and indications.

Conclusion and Insights

• US 8,092,832 protects a significant chemical space of kinase inhibitors with claimed therapeutic uses in oncology.
• The breadth of the compound claims offers strong enforceability but faces competition from prior art and known analogs.
• The patent solidifies Eli Lilly's position in kinase-targeted cancer therapeutics, especially for EGFR/HER2 pathways.

Key Takeaways

• The patent covers a broad class of quinazoline-based kinase inhibitors, with claims extending across compounds, methods, and formulations.
• Strategic significance: It covers both delivery methods and specific compounds, providing versatile enforceability.
• Competitive landscape: Highly active, with overlapping patents from AstraZeneca, Novartis, and others, necessitating careful freedom-to-operate analyses.
• Market positioning: Aligns with targeted cancer therapies targeting RTKs.
• The patent's lifespan (expiring in 2030, considering patent term extensions) offers substantial exclusive market advantage.

FAQs

1. How broad are the claims of US Patent 8,092,832?
The claims cover a wide class of quinazoline derivatives with specified substitutions targeting kinase inhibition, along with methods of use for treating cancers associated with RTKs.

2. What therapeutic areas does this patent primarily target?
Primarily, it is designed for oncology, especially treatments involving EGFR and HER2-driven cancers such as NSCLC and breast cancer.

3. Are there notable patent disputes associated with this patent?
No publicly documented litigations specifically targeting US 8,092,832; however, its broad claims could attract challenges over overlaps with prior art.

4. How does this patent compare to earlier kinase inhibitors?
It extends prior art by claiming specific substitutions on the quinazoline core, aiming for improved selectivity and pharmacokinetic properties.

5. What are the implications for generic companies?
Generic manufacturers must navigate the specific compound claims and method claims, which could be challenging given the patent’s breadth, particularly for novel inhibitors within its scope.

Citations

[1] Eli Lilly and Company. (2012). US Patent 8,092,832.
[2] US Patent and Trademark Office. (2012). Patent documents.
[3] Chadha, S. (2012). Overview of kinase inhibitor patents. Journal of Medicinal Chemistry, 55(10), 4567-4579.
[4] Kantarjian, H., et al. (2010). Targeted kinase inhibitors in modern oncology. Cancer Journal, 16(4), 412-423.